Combination Therapy With LIV1-ADC and PD-1 Antagonist
AssigneeSeagen Inc.
InventorsZejing Wang, Nicholas Choong, Django Sussman
Life of this patent
Estimating the term…
Abstract
The present disclosure relates, in general, to methods for treating LIV-1-expressing cancers comprising administering an anti-LIV-1 antibody drug conjugate (LIV-1-ADC) in combination with a PD-1 antagonist, such as an anti-PD-1 antibody.
Claims77
A method for treating a subject having or at risk of cancer, the method comprising administering to the subject a LIV-1 antibody drug conjugate (LIV-1-ADC) and a PD-1 antagonist selected from the group consisting of an anti-PD-1 antibody and an anti-PD-L1 antibody.
4-6. (canceled)
10-12. (canceled)
(canceled)
(canceled)
A method for treating a subject having or at risk of triple negative breast cancer, the method comprising administering to the subject a LIV-1 antibody drug conjugate (LIV-1-ADC) and a PD-1 antagonist selected from the group consisting of an anti-PD-1 antibody and an anti-PD-L1 antibody.
25-27. (canceled)
(canceled)
(canceled)
38-39. (canceled)
41-42. (canceled)
44-47. (canceled)
49-51. (canceled)
A method for treating a subject having de novo metastatic triple negative breast cancer, the method comprising administering to the subject a LIV-1 antibody drug conjugate (LIV-1-ADC) and a PD-1 antagonist selected from the group consisting of an anti-PD-1 antibody and an anti-PD-L1 antibody.
56-58. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
72-73. (canceled)
75-78. (canceled)
80-82. (canceled)
A method of treating a solid tumor that has metastasized or is at risk of metastasizing comprising administering to the subject a LIV-1 antibody drug conjugate (LIV-1-ADC), wherein the LIV-1-ADC is administered at a dosage between 1.0 mg/kg and 4 mg/kg of the subject's body weight.
(canceled)
A method of treating a solid tumor selected from the group consisting of non-small cell lung carcinoma (NSCLC) (squamous & non-squamous), small cell lung cancer, gastric/esophagogastric junction (GEJ) adenocarcinoma, esophageal squamous cell carcinoma, and head & neck squamous cell carcinoma comprising administering to the subject a LIV-1 antibody drug conjugate (LIV-1-ADC).
(canceled)
92-93. (canceled)
95-97. (canceled)
Dependencies are inferred from the claim text.